Rheumatologist ranks sits at the center of this dementia and brain health question.
If a rheumatologist had to rank these three drugs today, Skyrizi would sit at the top for most inflammatory conditions, followed by Rinvoq for patients who need oral convenience and have already tried a TNF inhibitor, with Humira landing in third — still a reasonable starting point, but increasingly outgunned in head-to-head studies. That ranking comes with serious caveats depending on your specific diagnosis, your cardiovascular risk factors, and whether you have tried and failed other treatments. A 55-year-old woman with rheumatoid arthritis and a history of smoking, for instance, would face a very different risk-benefit calculation than a 30-year-old man with moderate psoriasis and no other health concerns. All three of these drugs come from the same manufacturer, AbbVie, which reported record revenue of $61.1 billion in 2025.
Skyrizi has already overtaken Humira as AbbVie’s top-selling drug, pulling in $17.5 billion last year compared to Humira’s $4.5 billion — a dramatic fall for what was once the best-selling drug in the world. Rinvoq, meanwhile, generated $8.3 billion. These sales numbers reflect a real shift in how doctors are prescribing, and the reasons behind that shift matter if you are trying to make sense of your own treatment options. This article breaks down how each drug works, what the clinical data actually shows, the safety warnings you need to understand, what these medications cost in the real world, and how the choice changes depending on your specific condition. None of this replaces a conversation with your rheumatologist or dermatologist, but it should give you the information you need to have a more productive one.
Table of Contents
- What Are Humira, Skyrizi, and Rinvoq — and How Do They Actually Compare?
- Why Skyrizi Has Become the Preferred Biologic for Psoriasis and Beyond
- The FDA Black Box Warning on Rinvoq That Every Patient Should Understand
- How Do These Drugs Compare on Cost — and Can Anyone Actually Afford Them?
- When Humira Still Makes Sense — and When It Doesn’t
- How the Choice Changes by Condition — Psoriasis, RA, Crohn’s, and Psoriatic Arthritis
- Where the Market Is Headed in 2026 and Beyond
- Conclusion
- Frequently Asked Questions
What Are Humira, Skyrizi, and Rinvoq — and How Do They Actually Compare?
These three drugs attack inflammation through entirely different mechanisms, which is why their effectiveness and safety profiles vary so much. Humira, FDA-approved back in 2002, is a TNF inhibitor — a biologic that blocks tumor necrosis factor, one of the key proteins that drives inflammation. You inject it every other week. Skyrizi, approved in 2019, is an IL-23 inhibitor that targets a more specific part of the immune pathway. After initial loading doses, you only need an injection every two to three months. Rinvoq, also approved in 2019, is technically not a biologic at all. It is a JAK inhibitor, classified as a targeted synthetic DMARD, and it comes as a once-daily oral tablet — no injections required. That distinction between biologic and small molecule matters more than it might seem.
Biologics like Humira and Skyrizi are large, complex proteins grown in living cells, which is why they must be injected. Rinvoq is a small molecule you can swallow. The practical upside of Rinvoq is obvious: no needles, no refrigeration, no subcutaneous injection site reactions. But the tradeoff is that JAK inhibitors as a class have drawn serious FDA safety scrutiny, which we will get into shortly. Skyrizi, by contrast, has the cleanest safety profile of the three — no black box warning — while delivering what many specialists consider best-in-class efficacy for psoriasis and increasingly strong data in Crohn’s disease. For a direct comparison: in psoriasis trials, nearly 90 percent of patients on Skyrizi achieved clear or almost clear skin by week 16, and roughly 60 percent achieved complete clearance at week 52. In rheumatoid arthritis, the Phase 3b/4 SELECT-SWITCH study announced in October 2025 showed Rinvoq 15 mg once daily was superior to Humira 40 mg every other week at week 12 in patients who had already failed a TNF inhibitor. No new safety signals emerged from that trial, but the context matters — these were patients for whom Humira-type drugs had already stopped working.
Why Skyrizi Has Become the Preferred Biologic for Psoriasis and Beyond
The clinical data behind Skyrizi’s rise is not subtle. For plaque psoriasis, IL-23 inhibitors have largely displaced TNF inhibitors as the treatment rheumatologists and dermatologists reach for first. The reason is straightforward: better clearance rates, longer dosing intervals, and fewer safety concerns. When nearly 60 percent of patients on Skyrizi achieve complete skin clearance at one year — not just improvement, but total clearance — that sets a standard Humira cannot match in head-to-head comparisons. Beyond psoriasis, Skyrizi has made meaningful inroads in inflammatory bowel disease.
In two Phase III studies for Crohn’s disease, both doses of Skyrizi met co-primary endpoints of clinical remission and endoscopic response at week 12 versus placebo. For patients who have cycled through TNF inhibitors without adequate relief, or who lost response over time (a common problem with Humira), Skyrizi offers a genuinely different mechanism that may succeed where older drugs failed. However, Skyrizi is not the right choice for every patient or every condition. If you have rheumatoid arthritis specifically, Skyrizi is not approved for RA — its approvals center on psoriasis, psoriatic arthritis, and Crohn’s disease. A patient whose primary concern is joint inflammation from RA would not benefit from Skyrizi regardless of its impressive data elsewhere. This is one of the most important points lost in broad drug comparisons: the “best” biologic depends entirely on which disease you are treating.
The FDA Black Box Warning on Rinvoq That Every Patient Should Understand
Rinvoq carries an FDA black box warning — the most serious type of safety warning the agency issues — for increased risk of serious heart-related events, malignancies, blood clots, and death. This warning applies to the entire JAK inhibitor drug class and stems from a large postmarketing study that compared JAK inhibitors to TNF blockers in rheumatoid arthritis patients aged 50 and older who had at least one cardiovascular risk factor. The results were concerning enough that the FDA now requires Rinvoq to be reserved for patients who have had an inadequate response or intolerance to at least one TNF blocker before starting a JAK inhibitor. In practical terms, this means your rheumatologist cannot prescribe Rinvoq as a first-line treatment for rheumatoid arthritis. You need to have tried and failed something like Humira first.
Current and past smokers face additional elevated risk, which further narrows the patient population for whom Rinvoq makes sense without reservation. A 62-year-old former smoker with high blood pressure and RA would need a careful conversation with their doctor about whether the convenience of a daily pill justifies the potential cardiovascular and cancer risks — especially when injectable alternatives without black box warnings exist. That said, the SELECT-SWITCH data showed no new safety signals when Rinvoq was studied against Humira in TNF-failure patients, and many rheumatologists consider the absolute risk increase modest for younger patients without cardiovascular risk factors. The black box warning is a population-level finding that may not apply equally to every individual. But it is there for a reason, and dismissing it would be irresponsible. If your doctor suggests Rinvoq, ask specifically about your personal risk factors and whether the safety profile makes sense for your situation.
How Do These Drugs Compare on Cost — and Can Anyone Actually Afford Them?
The list prices for all three drugs are staggering, though what patients actually pay varies enormously based on insurance, manufacturer copay programs, and whether biosimilars are available. Skyrizi carries a list price of roughly $23,838 per dose, and since maintenance dosing runs every three months or so, that translates to over $95,000 per year at list price. After adjustments, first-year costs have been estimated at around $36,745 per patient, dropping to approximately $29,855 in subsequent years. Rinvoq lists at about $7,090 for a 30-day supply, putting annual costs above $85,000. Humira’s annual list price sits near $90,000, though biosimilar competition has driven actual costs down roughly 25 percent since patent expiry. The biosimilar landscape has changed the Humira equation significantly.
Nine or more manufacturers now produce adalimumab biosimilars, and Humira’s market share has eroded from near-total dominance to roughly 62 percent of the adalimumab market, with biosimilars capturing about 38 percent and trending toward an even split. Blue Shield of California reported slashing its adalimumab costs substantially through biosimilar adoption. For patients and insurers looking to control spending, biosimilar Humira may be the most economical option — even if it is no longer the most effective one. All three drugs offer manufacturer savings programs that can reduce out-of-pocket costs to as little as $5 per dose for eligible patients with commercial insurance. But these programs typically exclude patients on Medicare or Medicaid, leaving the most financially vulnerable populations exposed to the highest costs. If you are comparing these drugs and cost is a major factor, the conversation with your insurance company matters as much as the conversation with your doctor.
When Humira Still Makes Sense — and When It Doesn’t
Despite losing ground to newer competitors, Humira remains one of the most widely prescribed biologics in the world, and there are legitimate reasons a rheumatologist might still start a patient on it. For rheumatoid arthritis, TNF inhibitors remain common first-line biologics, and Humira has over two decades of safety data — a depth of long-term evidence that neither Skyrizi nor Rinvoq can match. For a patient newly diagnosed with RA who has no particular reason to prefer a newer agent, Humira or one of its biosimilars represents a well-understood, well-tolerated option with a known risk profile. The problem is that Humira increasingly loses in direct comparisons. The SELECT-SWITCH trial showed Rinvoq was superior for RA patients who had failed a TNF inhibitor.
In psoriasis, Skyrizi’s clearance rates make Humira look like a previous-generation treatment — because it is. And one of Humira’s most frustrating clinical realities is immunogenicity: over time, some patients develop antibodies against adalimumab, causing the drug to lose effectiveness. This secondary failure is a well-documented phenomenon that drives many patients to switch therapies after months or years of initial success. If your rheumatologist is recommending Humira in 2026, the most likely reason is that it is your first biologic, your insurance formulary favors it, or a biosimilar version makes it the most affordable option. None of those are bad reasons. But if Humira has already stopped working for you, the data strongly supports moving to either Skyrizi or Rinvoq depending on your diagnosis and risk factors — not trying another TNF inhibitor, which is increasingly seen as a less productive strategy.
How the Choice Changes by Condition — Psoriasis, RA, Crohn’s, and Psoriatic Arthritis
The ranking of these drugs shifts depending on which disease you are treating, and this is where blanket comparisons break down. For skin-only psoriasis, IL-23 inhibitors like Skyrizi have become first-line for many dermatologists — the clearance data is simply too strong to ignore, and the every-three-month dosing is far more convenient than Humira’s biweekly injections. For rheumatoid arthritis, Humira or its biosimilars typically come first, with Rinvoq positioned as a second-line option for patients who fail TNF therapy, per FDA labeling restrictions. For Crohn’s disease and ulcerative colitis, all three are approved, but Skyrizi and Rinvoq have been gaining market share as newer, more effective options. For psoriatic arthritis, which involves both skin and joint inflammation, the choice often depends on whether the skin or joint component is more troublesome — Skyrizi may be preferred when skin disease dominates, while Rinvoq’s oral convenience appeals when joints are the primary concern.
A patient with both psoriatic arthritis and a history of cardiovascular disease illustrates the complexity well. Rinvoq’s oral convenience would be attractive, but the black box warning makes it a harder sell for someone with heart risk factors. Skyrizi could address both skin and joint symptoms without the cardiovascular concern, making it the more cautious choice. Meanwhile, a biosimilar Humira might be preferred if cost is the overriding factor and the disease is well-controlled. There is no universal best drug here — only the best drug for a specific patient at a specific moment.
Where the Market Is Headed in 2026 and Beyond
AbbVie’s own projections tell the story clearly: the company expects Skyrizi and Rinvoq to generate a combined $34.5 billion in 2026, with total company revenue reaching approximately $67 billion — a 9.5 percent increase. Skyrizi alone grew over 50 percent year-over-year in the third quarter of 2024, posting $3.205 billion in a single quarter. Humira, meanwhile, continues its managed decline as biosimilars absorb more of the adalimumab market. By mid-2025, Humira usage was projected to drop to roughly 12 percent in certain indications.
For patients, the practical implication is that insurance formularies will continue shifting. Expect more plans to prefer Skyrizi or biosimilar adalimumab over branded Humira, and expect Rinvoq to remain positioned as a post-TNF-failure option unless the FDA revisits its JAK inhibitor restrictions based on newer safety data. The pipeline beyond these three drugs is active as well — newer IL-23 inhibitors, TYK2 inhibitors, and next-generation JAK inhibitors are all in development. But for the foreseeable future, the Humira-Skyrizi-Rinvoq decision is the one most patients with inflammatory disease will face, and understanding the tradeoffs has never been more important.
Conclusion
If you are forced to pick one, Skyrizi has the strongest argument across most inflammatory conditions in 2026 — best-in-class psoriasis clearance, strong Crohn’s disease data, no black box warning, and convenient dosing every two to three months. Rinvoq earns its place for patients who have failed TNF therapy and want an oral option, but the FDA safety restrictions and black box warning mean it is not a first-line drug for most people. Humira, once untouchable, is now a reasonable starting point rather than the gold standard — especially in biosimilar form where the cost savings are real.
The most important takeaway is that this decision is not one to make from a ranking alone. Your specific diagnosis, your cardiovascular and cancer risk profile, your treatment history, your insurance coverage, and your tolerance for injections versus pills all factor into which drug is right for you. Bring this information to your rheumatologist or dermatologist and have a direct conversation about where you fall in the risk-benefit landscape. The data is better than ever, but it only helps if you use it.
Frequently Asked Questions
Is Rinvoq a biologic?
No. Despite being grouped with biologics in many comparisons, Rinvoq is a JAK inhibitor classified as a targeted synthetic DMARD. It is a small molecule taken as an oral tablet, not a biologic protein that requires injection. This distinction matters because it affects how the drug is manufactured, how it interacts with the immune system, and why its safety profile differs from true biologics like Humira and Skyrizi.
Can I start Rinvoq without trying Humira first?
For rheumatoid arthritis, generally no. The FDA requires that Rinvoq be reserved for patients who have had an inadequate response or intolerance to at least one TNF blocker like Humira. For other approved conditions like psoriatic arthritis or ulcerative colitis, the prescribing requirements may differ — ask your specialist about the current labeling for your specific diagnosis.
How much will I actually pay out of pocket for Skyrizi?
It depends heavily on your insurance. Skyrizi’s list price runs over $95,000 per year, but AbbVie offers a manufacturer savings card that can reduce costs to as low as $5 per dose for patients with commercial insurance. Patients on Medicare or Medicaid typically do not qualify for these programs and may face significantly higher out-of-pocket costs. First-year costs after adjustments have been estimated at around $36,745 per patient.
Why is my doctor still prescribing Humira if newer drugs are better?
Several valid reasons. Humira has over 20 years of safety data, which gives doctors confidence in its long-term risk profile. It may also be preferred by your insurance formulary, especially in biosimilar form where costs are roughly 25 percent lower than branded Humira. For a first-time biologic user with rheumatoid arthritis, starting with a TNF inhibitor like Humira is still standard practice — newer options like Rinvoq are typically reserved for patients who do not respond adequately to TNF therapy.
Are Humira biosimilars just as effective as brand-name Humira?
Yes. Biosimilars are required by the FDA to demonstrate no clinically meaningful differences from the reference product in terms of safety, purity, and potency. Nine or more manufacturers now produce adalimumab biosimilars, and their adoption has driven significant cost savings — Blue Shield of California reported substantial reductions in adalimumab spending after switching to biosimilars. If your doctor or insurance plan suggests a biosimilar, the clinical evidence supports that switch.
Does smoking affect which drug I should choose?
It can, particularly with Rinvoq. The FDA black box warning on JAK inhibitors specifically notes that current and former smokers face additional increased risk of serious cardiovascular events, malignancies, and blood clots. If you smoke or have a smoking history, your doctor may steer you toward Skyrizi or a TNF inhibitor instead of Rinvoq, especially if you also have other cardiovascular risk factors like high blood pressure or elevated cholesterol.
You Might Also Like
- Growth Hormone for Adults: When It’s Medically Necessary vs. Abuse
- Condom vs. The Pill vs. IUD: Real Effectiveness Numbers Most People Get Wrong
- Why Some Human Drugs Work in Pets — But Others Are Deadly
For more, see Alzheimer’s Association — clinical trials.
